Cancer Therapeutics CRC (CTX) is pleased to announce the appointment of Dr Brendon Monahan as Chief Scientific Officer. Brendon will succeed Dr Ian Street who was co-founder of CTX in 2007, and who will continue to provide services to the organisation in an advisory capacity. This change is part of CTX’s transition plan for the business as it prepares for a future beyond the CRC program.
Commenting on the appointment, Mr Brett Cater, CEO of CTX, said: “We are delighted to appoint Brendon as Chief Scientific Officer. Brendon has all of the attributes you could wish for in a CSO; deep scientific and drug discovery knowledge, an innate ability to direct and develop teams, and excellent communication skills. These skills, along with Brendon’s tenacity and leadership were critical to execution of the $670 million Pfizer deal we completed in October and will serve CTX well as we develop and implement our scientific strategy moving forward. I would like to thank Ian for his dedication to the organisation over the past 10 years. Ian has made many contributions to CTX and I would like to specifically highlight delivery of both the Merck PRMT5 and the Pfizer Chromatin Modifying Enzyme licensing deals, two of Australia’s largest ever pre-clinical asset licensing deals which could result in more than $1 billion being returned to Australia.”
Commenting on the appointment, Dr Monahan, said: “It is an honour and privilege to be appointed CSO of CTx. It’s a great team, filled with passionate, dedicated and talented people and I look forward to working together to deliver more successful outcomes. Drug discovery is an incredible field and I’m extremely grateful to Ian for showing me the way and I am extremely pleased he will be continuing on with CTx in an advisory role.”